J&J to Acquire Halda Therapeutics for $3.05B

New Haven, CT, November 17, 2025 (Reuters) -- Johnson & Johnson will acquire Halda Therapeutics in a $3.05 billion all-cash deal aimed at accelerating Halda’s RIPTAC™ platform for solid tumors. The lead candidate, HLD-0915, recently reported promising Phase 1/2 results in metastatic castration-resistant prostate cancer, showing good tolerability along with reductions in PSA levels and RECIST-based tumor responses. Halda’s broader pipeline includes multiple RIPTAC programs targeting major solid tumors and other serious diseases, which J&J plans to advance following the acquisition.

Read full article here.